Literature DB >> 18381103

Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma.

Brad Kahl1.   

Abstract

Although the use of monoclonal antibodies as single agents has had a tremendous impact on the care of patients with non-Hodgkin's lymphoma (NHL), the greatest benefit has been generated by the addition of monoclonal antibodies to conventional cytotoxic chemotherapy. Rituximab is the monoclonal antibody responsible for all clinical improvement noted to date. The addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy (R-CHOP regimen) improves the response rate, progression-free survival (PFS), and overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). Adding rituximab to CHOP chemotherapy improves response rates and PFS in mantle cell lymphoma (MCL). Finally, the addition of rituximab to a variety of chemotherapy regimens improves the response rates, PFS, and OS in follicular lymphoma (FL). Several other (epratuzumab, bevacizumab, alemtuzumab) monoclonal antibody-chemotherapy combinations are currently under study in NHL. This review will summarize the data supporting the addition of rituximab to chemotherapy in NHL and discuss preliminary data regarding the use of other monoclonal antibodies in combination with chemotherapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18381103      PMCID： PMC2919066          DOI： 10.1053/j.seminhematol.2008.02.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  25 in total

1.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.

Authors:  Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

2.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.

Authors:  Wolfgang Hiddemann; Michael Kneba; Martin Dreyling; Norbert Schmitz; Eva Lengfelder; Rudolf Schmits; Marcel Reiser; Bernd Metzner; Harriet Harder; Susanna Hegewisch-Becker; Thomas Fischer; Martin Kropff; Hans-Edgar Reis; Mathias Freund; Bernhard Wörmann; Roland Fuchs; Manfred Planker; Jörg Schimke; Hartmut Eimermacher; Lorenz Trümper; Ali Aldaoud; Reza Parwaresch; Michael Unterhalt
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

3.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

4.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Lorenz Trümper; Anders Osterborg; Ruth Pettengell; Marek Trneny; Kevin Imrie; David Ma; Devinder Gill; Jan Walewski; Pier-Luigi Zinzani; Rolf Stahel; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Tuula Lehtinen; Armando López-Guillermo; Claudia Corrado; Adriana Scheliga; Noel Milpied; Myriam Mendila; Michelle Rashford; Evelyn Kuhnt; Markus Loeffler
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

Authors:  Laurie H Sehn; Jane Donaldson; Mukesh Chhanabhai; Catherine Fitzgerald; Karamjit Gill; Richard Klasa; Nicol MacPherson; Susan O'Reilly; John J Spinelli; Judy Sutherland; Kenneth S Wilson; Randy D Gascoyne; Joseph M Connors
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

6.  Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.

Authors:  John P Leonard; Morton Coleman; Jamie Ketas; Michelle Ashe; Jennifer M Fiore; Richard R Furman; Ruben Niesvizky; Tsiporah Shore; Amy Chadburn; Heather Horne; Jacqueline Kovacs; Cliff L Ding; William A Wegener; Ivan D Horak; David M Goldenberg
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

7.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.

Authors:  I S Lossos; A A Alizadeh; M B Eisen; W C Chan; P O Brown; D Botstein; L M Staudt; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

8.  Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.

Authors:  Sandra J Strauss; Frank Morschhauser; Juergen Rech; Roland Repp; Philippe Solal-Celigny; Pier L Zinzani; Andreas Engert; Bernard Coiffier; Dieter F Hoelzer; William A Wegener; Nick K W Teoh; David M Goldenberg; T Andrew Lister
Journal:  J Clin Oncol       Date:  2006-07-24       Impact factor: 44.544

9.  Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis.

Authors:  Kristen N Ganjoo; Caroline S An; Michael J Robertson; Leo I Gordon; Joy A Sen; Jill Weisenbach; Shuli Li; Edie A Weller; Attilio Orazi; Sandra J Horning
Journal:  Leuk Lymphoma       Date:  2006-06

10.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Nicolas Mounier; Josette Briere; Christian Gisselbrecht; Jean-Francois Emile; Pierre Lederlin; Catherine Sebban; Francoise Berger; Andre Bosly; Pierre Morel; Herve Tilly; Reda Bouabdallah; Felix Reyes; Philippe Gaulard; Bertrand Coiffier
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113
View more
  10 in total

1.  Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Authors:  Yvonne M Saenger; Yanyun Li; Karoline C Chiou; Brian Chan; Gabrielle Rizzuto; Stephanie L Terzulli; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

2.  Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.

Authors:  Rajen Mody; Alice L Yu; Arlene Naranjo; Fan F Zhang; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Jacquelyn A Hank; Mildred Felder; Jennifer Birstler; Paul M Sondel; Shahab Asgharzadeh; Julia Glade-Bender; Howard Katzenstein; John M Maris; Julie R Park; Rochelle Bagatell
Journal:  J Clin Oncol       Date:  2020-04-28       Impact factor: 44.544

3.  Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression.

Authors:  Yan Li; Maimaitili Yimamu; Xiaomin Wang; Xiaoyan Zhang; Min Mao; Ling Fu; Aihemaitijiang Aisimitula; Yuling Nie; Qin Huang
Journal:  Int J Hematol       Date:  2013-11-21       Impact factor: 2.490

4.  Discovery and canine preclinical assessment of a nontoxic procaspase-3-activating compound.

Authors:  Quinn P Peterson; Danny C Hsu; Chris J Novotny; Diana C West; Dewey Kim; Joanna M Schmit; Levent Dirikolu; Paul J Hergenrother; Timothy M Fan
Journal:  Cancer Res       Date:  2010-09-07       Impact factor: 12.701

5.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

Review 6.  Targeting minimal residual disease: a path to cure?

Authors:  Marlise R Luskin; Mark A Murakami; Scott R Manalis; David M Weinstock
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

7.  Chemotherapy-Induced Ischemic Colitis in a Patient with Jejunal Lymphoma.

Authors:  Ulrich Halm; Stephan Sack; Markus Zachäus
Journal:  Case Rep Gastroenterol       Date:  2010-10-21

Review 8.  Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma.

Authors:  Lidia Gil; Maciej Kazmierczak; Renata Kroll-Balcerzak; Mieczyslaw Komarnicki
Journal:  Med Oncol       Date:  2014-04-22       Impact factor: 3.064

Review 9.  Recent advances in the field of anti-cancer immunotherapy.

Authors:  Henrique Neves; Hang Fai Kwok
Journal:  BBA Clin       Date:  2015-04-18

10.  Primary hepatic lymphoma treated with liver resection followed by chemotherapy: a case report.

Authors:  Jeong-Ik Park; Bo-Hyun Jung
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2017-08-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.